search
Back to results

Medication Management Among Individuals With Neurodevelopmental Disabilities (M-MIND)

Primary Purpose

Spina Bifida, Cerebral Palsy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RL-adaptive application
Sponsored by
University of Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Spina Bifida focused on measuring Mobile technology, Reinforcement-learning, Medication management

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

For young adult:

  • Diagnosed with cerebral palsy or spina bifida and previously enrolled in HUM00081812
  • Age 18-26 years-old
  • Having mild-moderate cognition based on consultation with the investigators and the results of the following tests: iBRIEF Metacognition index T-Score, CVLT List A Free Recall T Score, ReyO Organization T-Score, PPVT Scaled Score, Tower Scaled Score, TRAQ question 4: Do participants take medications correctly and on their own?
  • Having adequate physical dexterity (to be able to open a pill box and use an iPad/tablet)
  • Taking two or more routine oral medicines in pill formulation
  • Being able to take capsules or tablets
  • Still living at home with their parent/legal guardian
  • Have Wi-Fi/Internet access at home

For parent/caregiver:

  • Being the parent/legal guardian of a person with aforementioned disability
  • Owning a cell phone
  • Have Wi-Fi/Internet access at home

Exclusion Criteria:

• Those who do not fulfill the inclusion criteria will be excluded from the study

Sites / Locations

  • University of Michigan

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RL-adaptive application

Arm Description

Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers). Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications.

Outcomes

Primary Outcome Measures

Prefer to continue to use RL-adaptive support after study is over
Qualitative feedback

Secondary Outcome Measures

Usefulness of the aspects of the RL-adaptive support
Qualitative feedback
Most and least helpful aspects of RL-adaptive support application
Qualitative feedback
Ease of use of RL-adaptive support application
Qualitative feedback

Full Information

First Posted
April 7, 2017
Last Updated
March 29, 2019
Sponsor
University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT03121651
Brief Title
Medication Management Among Individuals With Neurodevelopmental Disabilities
Acronym
M-MIND
Official Title
Medication Management Among Individuals With Neurodevelopmental Disabilities
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
November 11, 2016 (Actual)
Primary Completion Date
December 2018 (Actual)
Study Completion Date
December 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study to develop a reinforcement learning (RL)-adaptive visual and interactive support application (hereafter RL-adaptive support) to help young adults with spina bifida or cerebral palsy become more independent with medication management. Individuals with disabilities who are empowered to manage several aspects of their lives can ultimately be better integrated into and contribute more to society.
Detailed Description
In this study, an application will be iteratively developed and tested using RL-adaptive support for young adults with disabilities, with the goal to promote the transition to independent self-medication administration among young adults with cerebral palsy and spina bifida. Stochastic mathematical models of how individuals with varying levels of executive function and psychomotor skills will respond to the interventions (i.e. the different types and formats of messages) of the RL-adaptive support will be developed. Up to 6 dyads of individuals with disabilities and their caregivers were intended to be recruited to collaborate in defining the features and content of the RL-adaptive support. The investigators recruited 3 dyads. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each: young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team, young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app The goal was to reduce the number of caregiver prompts necessary for the medication pillbox to be opened. Using these data, the number and type of prompts necessary for the caregiver to open the electronic pillbox can be determined. In case the young adult does not open the electronic pillbox within two hours, the caregiver will be notified so that pills are not missed. In each step, the useful features of the system will be determined via qualitative and quantitative feedback with specific suggestions about how to improve this supportive system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spina Bifida, Cerebral Palsy
Keywords
Mobile technology, Reinforcement-learning, Medication management

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Unblinded pilot study with 1 intervention arm
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RL-adaptive application
Arm Type
Experimental
Arm Description
Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers). Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications.
Intervention Type
Device
Intervention Name(s)
RL-adaptive application
Intervention Description
Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each: young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team, young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app. The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened.
Primary Outcome Measure Information:
Title
Prefer to continue to use RL-adaptive support after study is over
Description
Qualitative feedback
Time Frame
at least 18 weeks after beginning study
Secondary Outcome Measure Information:
Title
Usefulness of the aspects of the RL-adaptive support
Description
Qualitative feedback
Time Frame
End of each phase, which lasts approximately 6 weeks
Title
Most and least helpful aspects of RL-adaptive support application
Description
Qualitative feedback
Time Frame
End of each phase, which lasts approximately 6 weeks
Title
Ease of use of RL-adaptive support application
Description
Qualitative feedback
Time Frame
End of each phase, which lasts approximately 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For young adult: Diagnosed with cerebral palsy or spina bifida and previously enrolled in HUM00081812 Age 18-26 years-old Having mild-moderate cognition based on consultation with the investigators and the results of the following tests: iBRIEF Metacognition index T-Score, CVLT List A Free Recall T Score, ReyO Organization T-Score, PPVT Scaled Score, Tower Scaled Score, TRAQ question 4: Do participants take medications correctly and on their own? Having adequate physical dexterity (to be able to open a pill box and use an iPad/tablet) Taking two or more routine oral medicines in pill formulation Being able to take capsules or tablets Still living at home with their parent/legal guardian Have Wi-Fi/Internet access at home For parent/caregiver: Being the parent/legal guardian of a person with aforementioned disability Owning a cell phone Have Wi-Fi/Internet access at home Exclusion Criteria: • Those who do not fulfill the inclusion criteria will be excluded from the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen B Farris, PhD
Organizational Affiliation
Professor and Chair, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share IPD

Learn more about this trial

Medication Management Among Individuals With Neurodevelopmental Disabilities

We'll reach out to this number within 24 hrs